TGTX - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan tgtherapeutics.com

TG Therapeutics Inc (TGTX) - logo korporat

Stable demand for neurology and oncology drugs provides TG Therapeutics, Inc. (TGTX) with a steady cash flow. The EV/EBITDA valuation multiple demonstrates that the current status equals 51.90. Revenues are based on the sale of targeted agents against B-cell neoplasms and multiple sclerosis. The strategy relies exclusively on organic sales growth without engaging in external mergers and acquisitions.

TGTX TG Therapeutics Corp: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ing interval 23.11.2025 - 15.11.2026

TG Therapeutics Corp - rincian analitis lan metrik utama (TGTX)

- rega saiki lan proyeksi nilai saham:
Analisis umum perusahaan:TG Pharma TGTX
Sampel barang TG Therapeutics Inc

This metric compares the total value of assets and liabilities with cash flow before taxes and depreciation, allowing for an assessment of the business's real value regardless of the debt load. Given the stable US jurisdiction and the humanitarian status of TG Therapeutics, Inc. (TGTX) developments, the enterprise value to EBITDA multiple clearly demonstrates the efficiency of capitalizing biopharmaceutical innovations in the current economic cycle.